ClinicalTrials.gg
CompletedNCT05281510Updated Jan 16, 2026Results posted

Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women

A Phase 2 interventional study of Vesatolimod and VRC07523LS in HIV-1-infection, sponsored by Gilead Sciences. Completed at 1 site in South Africa. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 years
  • Females recruited from the Females Rising through Education, Support, and Health (FRESH) acute (HIV) infection cohort.
  • Plasma human immunodeficiency -1 (HIV-1) ribonucleic acid (RNA) levels \< 50 copies/mL at the screening visit.
  • On antiretroviral (ART) regimen for ≥ 12 consecutive months prior to the screening visit.
  • Have all the following laboratory values at the screening visit:

    • ≥ 10.0 g/dL
    • White blood cells ≥ 2500 cells/μL
    • ≥ 125,000/mL
    • ≥ 1000 cells/μL
    • Cluster of differentiation (CD)4+ T cell count ≥ 500 cells/μL
    • (ALT), aspartate aminotransferase (AST), and ≤ 2 × (ULN)
    • ≥ 60 mL/min
  • Women of to have documentation of agreement to follow study requirements.
  • Documented plasma HIV-1 RNA \< 50 copies/mL for 12 consecutive months prior to the screening visit.
  • In the judgment of the investigator, be in good general health.
  • Documented history of viral sensitivity to VRC07-523LS or CAP256V2LS at the screening visit.

Key Exclusion Criteria:

  • Have poor venous access that limits phlebotomy.
  • Positive serum pregnancy test.
  • Nursing participants.
  • Females with coinfection and/or as described below:

    • disease requiring ongoing immunosuppression
    • Evidence of chronic virus (HBV) infection
    • Evidence of current virus (HCV) infection
    • Documented history of pre-ART nadir \< 200 cells/μL
    • History of opportunistic illness indicative of Stage 3 HIV
    • Acute febrile illness within 4 weeks prior to the first dose
  • Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual's compliance or individual's safety.
  • Have been treated with systemic , immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or are expected to receive these agents during the study.
  • Have previous or current receipt of humanized or human monoclonal antibody (mAbs), or polyclonal immunoglobulin.
  • Have previous history of an antidrug antibodies response to a therapeutic agent.
  • Have previous receipt of an HIV vaccine.
  • Received any vaccine or immunomodulatory medication within 4 weeks prior to screening.
  • Have a history of any of the following:

    • Significant serious skin disease
    • Significant drug sensitivity or drug allergy
    • Known to the study drugs, metabolites, or formulation
    • Previous or current history of bleeding disorder, platelet disorder including unexplained acute or chronic thrombocytopenia
    • Autoimmune diseases including type 1 diabetes mellitus
  • Have current Class C acquired immunodeficiency syndrome (AIDS)-defining condition.
  • Have any serious or active medical or psychiatric illness that would interfere with participants treatment, assessment, or compliance with the protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    VRC07523LS + CAP256V2LS + Vesatolimod (VES)

    In Period 1 (Days 0-28), participants will receive ART through Period. On Days 0 \& 14, participants will be administered VES 6mg orally and on Day 28, participants will be administered VES either 6 or 8mg orally. VRC07-523LS \& CAP256V2LS 20mg/kg will be administered intravenously on Day 7. In Period 2 (Days 29-133 or until ART restart), participants will discontinue ART at Day 35 and remain off ART until reaching ART restart criteria. Participants will receive VES 6 or 8mg orally every 2 weeks from Day 29 or until plasma HIV-1 RNA is \>=5000 copies/mL. In Period 3, (Days 134-336 or until ART restart), participants will continue ATI and no study treatment will be administered. In Period 4, (Days 337-413) participants who have not met ART restart criteria by Day 337 may choose to restart ART (Period 4a) or may choose to continue ATI until end of study (Period 4B). Any participants who meet ART restart criteria before the end of the study will remain in follow-up on ART (Period 4A).

    Drug: Vesatolimod · Biological: VRC07523LS · Biological: CAP256V2LS

Interventions

  • Administered orally

    Also known as: GS-9620

  • BiologicalVRC07523LS

    Administered intravenously

  • BiologicalCAP256V2LS

    Administered intravenously

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAE was defined as any AE that began on or after the study drug start date and no later than last exposure date after permanent discontinuation of study drug, or led to premature study drug discontinuation.

    Time frame: Up to 61.1 weeks

  2. Percentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the last exposure date after permanent discontinuation of study drug. For maximum postbaseline toxicity grade, the most severe graded abnormality from all tests was counted for each participant. The severity grades were defined by Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, Antiviral Toxicity Grading Scale, Version 01 April 2015. The CTCAE v5 grading scale was used to grade AEs determined to be cytokine release syndrome and infusion-related reactions. The grading for both scales are as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-Threatening, Grade 5 = Death.

    Time frame: Up to 61.1 weeks

Secondary outcomes

  1. Time to Viral Rebound (Confirmed ≥ 50 Copies/mL and ≥ 200 Copies/mL) Following ATI

    Virologic rebound is defined as at any visit a rebound in HIV-1 RNA to ≥ 50 copies/mL or ≥ 200 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit. Time to rebound (in weeks) = (date of rebound or censoring date - ATI start date + 1) / 7.

    Time frame: Up to 56 weeks

  2. Change in Plasma Viral Load Set-point Following ATI

    Change in plasma viral load set-point between pre-ART value and prior to ART reinitiation following ATI was summarized. The pre-ART set point value is the HIV-RNA load count prior to start of initial ARV treatment recorded in the clinical database.

    Time frame: Pre-ART (Screening) and prior to ART reinitiation following ATI (Up to 56 weeks)

  3. Change From Baseline of Viral Load at the End of ATI

    Baseline value was the last available value collected on or prior to first dose of study drug.

    Time frame: Up to 48 weeks

  4. Time to ART Resumption Following ATI

    Time to ART resumption (in weeks) = (date of restart ART after ATI period start or censoring date - ATI start date + 1) / 7.

    Time frame: Up to 56 weeks

  5. Pharmacokinetic (PK) Parameter of VES: Cmax

    Cmax is defined as maximum observed concentration of drug.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  6. PK Parameter of VES: Tmax

    Tmax is defined as time (observed time point) of Cmax.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  7. PK Parameter of VES: Clast

    Clast is defined as last observed quantifiable concentration of the drug.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  8. PK Parameter of VES: Tlast

    Tlast is defined as time (observed time point) of Clast.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  9. PK Parameter of VES: AUCinf

    AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  10. PK Parameter of VES: AUClast

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  11. PK Parameter of VES: AUCexp

    AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  12. PK Parameter of VES: t1/2

    t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  13. PK Parameter of VES: CL/F

    CL/F is defined as apparent clearance following extravascular administration.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  14. PK Parameter of VES: Vz/F

    Vz/F is defined as apparent volume of distribution during the terminal phase following extravascular administration.

    Time frame: Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose

  15. PK Parameter of VRC07-523LS: Cmax

    Cmax is defined as maximum observed concentration of drug.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  16. PK Parameter of VRC07-523LS: Tmax

    Tmax is defined as time (observed time point) of Cmax.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  17. PK Parameter of VRC07-523LS: Clast

    Clast is defined as last observed quantifiable concentration of the drug.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  18. PK Parameter of VRC07-523LS: Tlast

    Tlast is defined as time (observed time point) of Clast.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  19. PK Parameter of VRC07-523LS: AUCinf

    AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  20. PK Parameter of VRC07-523LS: AUClast

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  21. PK Parameter of VRC07-523LS: AUCexp

    AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  22. PK Parameter of VRC07-523LS: t1/2

    t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  23. PK Parameter of VRC07-523LS: Clearance (CL)

    CL is defined as clearance following intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  24. PK Parameter of VRC07-523LS: Vss

    Vss is defined as the volume of distribution at steady-state following intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  25. PK Parameter of VRC07-523LS: Vz

    Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  26. PK Parameter of CAP256V2LS: Cmax

    Cmax is defined as maximum observed concentration of drug.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  27. PK Parameter of CAP256V2LS: Tmax

    Tmax is defined as time (observed time point) of Cmax.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  28. PK Parameter of CAP256V2LS: Clast

    Clast is defined as last observed quantifiable concentration of the drug.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  29. PK Parameter of CAP256V2LS: Tlast

    Tlast is defined as time (observed time point) of Clast.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  30. PK Parameter of CAP256V2LS: AUCinf

    AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  31. PK Parameter of CAP256V2LS: AUClast

    AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  32. PK Parameter of CAP256V2LS: AUCexp

    AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  33. PK Parameter of CAP256V2LS: t1/2

    t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  34. PK Parameter of CAP256V2LS: CL

    CL is defined as clearance following intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  35. PK Parameter of CAP256V2LS: Vz

    Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  36. PK Parameter of CAP256V2LS: Vss

    Vss is defined as the volume of distribution at steady-state after intravenous administration.

    Time frame: Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413

  37. Percentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies

    Time frame: Prebaseline (Day -13) up to Day 413

  38. Percentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies

    Time frame: Prebaseline (Day -13) up to Day 413

07

Results

Posted Jan 16, 2026

Participant flow

Participants were enrolled at a study site in South Africa.

Participant flow — Overall Study
MilestoneVRC07-523LS + CAP256V2LS + Vesatolimod (VES)
Started20
Completed20
Not completed0

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant administered a study drug that does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a study drug, whether or not the AE is considered related to the study drug. TEAE was defined as any AE that began on or after the study drug start date and no later than last exposure date after permanent discontinuation of study drug, or led to premature study drug discontinuation.

Time frame:
Up to 61.1 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
percentage of participantsVRC07-523LS + CAP256V2LS + VES
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)95
PrimaryPercentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from baseline at any time postbaseline up to and including the last exposure date after permanent discontinuation of study drug. For maximum postbaseline toxicity grade, the most severe graded abnormality from all tests was counted for each participant. The severity grades were defined by Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, Antiviral Toxicity Grading Scale, Version 01 April 2015. The CTCAE v5 grading scale was used to grade AEs determined to be cytokine release syndrome and infusion-related reactions. The grading for both scales are as follows: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-Threatening, Grade 5 = Death.

Time frame:
Up to 61.1 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-emergent Graded Laboratory Abnormalities
percentage of participantsVRC07-523LS + CAP256V2LS + Vesatolimod (VES)
Any Grade 1 or Higher95
Grade 120
Grade 240
Grade 335
Grade 40
SecondaryTime to Viral Rebound (Confirmed ≥ 50 Copies/mL and ≥ 200 Copies/mL) Following ATI

Virologic rebound is defined as at any visit a rebound in HIV-1 RNA to ≥ 50 copies/mL or ≥ 200 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit. Time to rebound (in weeks) = (date of rebound or censoring date - ATI start date + 1) / 7.

Time frame:
Up to 56 weeks
Reported as:
Median · weeks
Time to Viral Rebound (Confirmed ≥ 50 Copies/mL and ≥ 200 Copies/mL) Following ATI
weeksVRC07-523LS + CAP256V2LS + VES
Confirmed ≥ 50 copies/mL11.00 (7.00 to 19.07)
Confirmed ≥ 200 copies/mL11.00 (7.00 to 19.14)
SecondaryChange in Plasma Viral Load Set-point Following ATI

Change in plasma viral load set-point between pre-ART value and prior to ART reinitiation following ATI was summarized. The pre-ART set point value is the HIV-RNA load count prior to start of initial ARV treatment recorded in the clinical database.

Time frame:
Pre-ART (Screening) and prior to ART reinitiation following ATI (Up to 56 weeks)
Reported as:
Median · log10 copies/mL
Change in Plasma Viral Load Set-point Following ATI
log10 copies/mLVRC07-523LS + CAP256V2LS + VES
Change in Plasma Viral Load Set-point Following ATI-1.42 (-1.85 to -0.77)
Statistical analysis
  • VRC07-523LS + CAP256V2LS + VES · Wilcoxon signed rank test · p = 0.0020
SecondaryChange From Baseline of Viral Load at the End of ATI

Baseline value was the last available value collected on or prior to first dose of study drug.

Time frame:
Up to 48 weeks
Reported as:
Median · log10 copies/mL
Change From Baseline of Viral Load at the End of ATI
log10 copies/mLVRC07-523LS + CAP256V2LS + VES
Change From Baseline of Viral Load at the End of ATI2.96 (1.58 to 4.07)
SecondaryTime to ART Resumption Following ATI

Time to ART resumption (in weeks) = (date of restart ART after ATI period start or censoring date - ATI start date + 1) / 7.

Time frame:
Up to 56 weeks
Reported as:
Median · weeks
Time to ART Resumption Following ATI
weeksVRC07-523LS + CAP256V2LS + VES
Time to ART Resumption Following ATI24.21 (12.64 to 47.14)
SecondaryPharmacokinetic (PK) Parameter of VES: Cmax

Cmax is defined as maximum observed concentration of drug.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · pg/mL
Pharmacokinetic (PK) Parameter of VES: Cmax
pg/mLVRC07-523LS + CAP256V2LS + VES
Pharmacokinetic (PK) Parameter of VES: Cmax6350 ± 4220
SecondaryPK Parameter of VES: Tmax

Tmax is defined as time (observed time point) of Cmax.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Median · hours (h)
PK Parameter of VES: Tmax
hours (h)VRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: Tmax2.00 (0.833 to 8.00)
SecondaryPK Parameter of VES: Clast

Clast is defined as last observed quantifiable concentration of the drug.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · pg/mL
PK Parameter of VES: Clast
pg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: Clast279 ± 177
SecondaryPK Parameter of VES: Tlast

Tlast is defined as time (observed time point) of Clast.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Median · h
PK Parameter of VES: Tlast
hVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: Tlast48.0 (47.1 to 49.7)
SecondaryPK Parameter of VES: AUCinf

AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · h*pg/mL
PK Parameter of VES: AUCinf
h*pg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: AUCinf62700 ± 37700
SecondaryPK Parameter of VES: AUClast

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · h*pg/mL
PK Parameter of VES: AUClast
h*pg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: AUClast55500 ± 34200
SecondaryPK Parameter of VES: AUCexp

AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · percent
PK Parameter of VES: AUCexp
percentVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: AUCexp12.4 ± 6.68
SecondaryPK Parameter of VES: t1/2

t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Median · h
PK Parameter of VES: t1/2
hVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: t1/215.9 (10.4 to 27.0)
SecondaryPK Parameter of VES: CL/F

CL/F is defined as apparent clearance following extravascular administration.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · Liters (L)/h
PK Parameter of VES: CL/F
Liters (L)/hVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: CL/F144 ± 112
SecondaryPK Parameter of VES: Vz/F

Vz/F is defined as apparent volume of distribution during the terminal phase following extravascular administration.

Time frame:
Day 1: Predose (≤ 5 minutes prior to dosing), 1, 2, 4, 8, 12, 24, and 48 hours postdose
Reported as:
Mean · L
PK Parameter of VES: Vz/F
LVRC07-523LS + CAP256V2LS + VES
PK Parameter of VES: Vz/F3810 ± 3650
SecondaryPK Parameter of VRC07-523LS: Cmax

Cmax is defined as maximum observed concentration of drug.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · µg/mL
PK Parameter of VRC07-523LS: Cmax
µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Cmax481 ± 83.5
SecondaryPK Parameter of VRC07-523LS: Tmax

Tmax is defined as time (observed time point) of Cmax.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · h
PK Parameter of VRC07-523LS: Tmax
hVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Tmax0.550 (0.467 to 4.83)
SecondaryPK Parameter of VRC07-523LS: Clast

Clast is defined as last observed quantifiable concentration of the drug.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · µg/mL
PK Parameter of VRC07-523LS: Clast
µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Clast3.51 ± 2.98
SecondaryPK Parameter of VRC07-523LS: Tlast

Tlast is defined as time (observed time point) of Clast.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · day
PK Parameter of VRC07-523LS: Tlast
dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Tlast238 (147 to 336)
SecondaryPK Parameter of VRC07-523LS: AUCinf

AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · day*µg/mL
PK Parameter of VRC07-523LS: AUCinf
day*µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: AUCinf7540 ± 1360
SecondaryPK Parameter of VRC07-523LS: AUClast

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · day*µg/mL
PK Parameter of VRC07-523LS: AUClast
day*µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: AUClast7320 ± 1340
SecondaryPK Parameter of VRC07-523LS: AUCexp

AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · percent
PK Parameter of VRC07-523LS: AUCexp
percentVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: AUCexp2.94 ± 2.71
SecondaryPK Parameter of VRC07-523LS: t1/2

t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · day
PK Parameter of VRC07-523LS: t1/2
dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: t1/241.9 (25.7 to 60.5)
SecondaryPK Parameter of VRC07-523LS: Clearance (CL)

CL is defined as clearance following intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L/day
PK Parameter of VRC07-523LS: Clearance (CL)
L/dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Clearance (CL)0.198 ± 0.0513
SecondaryPK Parameter of VRC07-523LS: Vss

Vss is defined as the volume of distribution at steady-state following intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L
PK Parameter of VRC07-523LS: Vss
LVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Vss11.5 ± 2.54
SecondaryPK Parameter of VRC07-523LS: Vz

Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L
PK Parameter of VRC07-523LS: Vz
LVRC07-523LS + CAP256V2LS + VES
PK Parameter of VRC07-523LS: Vz12.0 ± 3.96
SecondaryPK Parameter of CAP256V2LS: Cmax

Cmax is defined as maximum observed concentration of drug.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · µg/mL
PK Parameter of CAP256V2LS: Cmax
µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Cmax644 ± 309
SecondaryPK Parameter of CAP256V2LS: Tmax

Tmax is defined as time (observed time point) of Cmax.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · h
PK Parameter of CAP256V2LS: Tmax
hVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Tmax1.50 (0.500 to 4.50)
SecondaryPK Parameter of CAP256V2LS: Clast

Clast is defined as last observed quantifiable concentration of the drug.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · µg/mL
PK Parameter of CAP256V2LS: Clast
µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Clast1.52 ± 0.493
SecondaryPK Parameter of CAP256V2LS: Tlast

Tlast is defined as time (observed time point) of Clast.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · day
PK Parameter of CAP256V2LS: Tlast
dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Tlast172 (126 to 321)
SecondaryPK Parameter of CAP256V2LS: AUCinf

AUCinf is defined as area under the concentration versus time curve extrapolated to infinite time, calculated as AUClast + (Clast/λz).

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · day*µg/mL
PK Parameter of CAP256V2LS: AUCinf
day*µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: AUCinf4290 ± 729
SecondaryPK Parameter of CAP256V2LS: AUClast

AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · day*µg/mL
PK Parameter of CAP256V2LS: AUClast
day*µg/mLVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: AUClast4230 ± 710
SecondaryPK Parameter of CAP256V2LS: AUCexp

AUCexp is defined as AUC extrapolated between AUClast and AUCinf.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · percent
PK Parameter of CAP256V2LS: AUCexp
percentVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: AUCexp1.58 ± 0.452
SecondaryPK Parameter of CAP256V2LS: t1/2

t1/2 is defined as estimate of the terminal elimination half-life of the drug, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Median · day
PK Parameter of CAP256V2LS: t1/2
dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: t1/231.4 (20.2 to 77.8)
SecondaryPK Parameter of CAP256V2LS: CL

CL is defined as clearance following intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L/day
PK Parameter of CAP256V2LS: CL
L/dayVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: CL0.352 ± 0.116
SecondaryPK Parameter of CAP256V2LS: Vz

Vz is defined as volume of distribution of the drug during the terminal phase after intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L
PK Parameter of CAP256V2LS: Vz
LVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Vz15.3 ± 3.72
SecondaryPK Parameter of CAP256V2LS: Vss

Vss is defined as the volume of distribution at steady-state after intravenous administration.

Time frame:
Day 7: Predose (0 hours), end of infusion, 1, 2, 4, and 8 hours after end of infusion, and then anytime on Days 8, 9, 14, 21, 28, 56, 84, 112, 133, 161, 189, 217, 245, 273, 301, 329, 343, 371, and 413
Reported as:
Mean · L
PK Parameter of CAP256V2LS: Vss
LVRC07-523LS + CAP256V2LS + VES
PK Parameter of CAP256V2LS: Vss10.6 ± 2.21
SecondaryPercentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies
Time frame:
Prebaseline (Day -13) up to Day 413
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies
percentage of participantsVRC07-523LS + CAP256V2LS + VES
Percentage of Participants With Treatment-emergent Positive Anti-VRC07-523LS Antibodies15.0
SecondaryPercentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies
Time frame:
Prebaseline (Day -13) up to Day 413
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies
percentage of participantsVRC07-523LS + CAP256V2LS + VES
Percentage of Participants With Treatment-emergent Positive Anti-CAP256V2LS Antibodies55

Adverse events

Collected over All-Cause Mortality and Adverse Events: Up to 61.1 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VRC07-523LS + CAP256V2LS + VES0/20 (0%)2/20 (10%)19/20 (95%)
Most frequent serious events
Most frequent serious events
EventVRC07-523LS + CAP256V2LS + VES
CellulitisInfections and infestations1/20
OverdoseInjury, poisoning and procedural complications1/20
Intentional self-injuryPsychiatric disorders1/20
Most frequent other events
Showing 10 of 52
Most frequent other events
EventVRC07-523LS + CAP256V2LS + VES
Infusion related reactionInjury, poisoning and procedural complications18/20
HeadacheNervous system disorders14/20
TachycardiaCardiac disorders8/20
PyrexiaGeneral disorders7/20
Haemoglobin decreasedInvestigations7/20
NauseaGastrointestinal disorders5/20
Chest discomfortGeneral disorders5/20
FatigueGeneral disorders4/20
Upper respiratory tract infectionInfections and infestations4/20
AnaemiaBlood and lymphatic system disorders3/20

Baseline characteristics

The Safety Analysis Set included all enrolled participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
<=18 years0
Between 18 and 65 years20
>=65 years0
Age, Continuous
Age, Continuous(years)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
Mean27 ± 2.4
Sex: Female, Male
Sex: Female, Male(Participants)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
Female20
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
Hispanic or Latino0
Not Hispanic or Latino20
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American20
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)VRC07-523LS + CAP256V2LS + Vesatolimod (VES)
South Africa20
08

Study locations

1 site
  • FRESH Clinical Research Site: Females Rising through Education, Support and Health
    Umlazi, 4066, South Africa
09

References and documents

Publications

  • Dong K, Asari V, Govender V, et al. Evaluation of 2 bNAbs plus vesatolimod in early-treated South African women with HIV-1 during ATI [CROI abstract 105]. Top Antivir Med. 2025;33:14
  • Omange RW, Zhang L, Reddy K, et al. Presence of protective human leukocyte antigen class I and II is associated with improved analytical treatment interruption outcomes in a trial of vesatolimod and broadly neutralizing antibodies in South African women with early-treated clade C HIV-1. Presented at the Keystone HIV Cure: Antiretroviral Therapy-Free Control of HIV Infection Symposium; April 7-10, 2025; Durban, South Africa. Poster 2014.
  • Dong K, SenGupta D, Gama L, et al. First HIV cure interventional trial in Africa with collaboration between academia, government, and industry. Presented at the 13th International AIDS Society (IAS) Conference on HIV Science; July 13-17, 2025; Kigali, Rwanda. ePoster EP1003.
  • Cai Y, Zhang L, Omange RW, et al. Vesatolimod pharmacodynamic responses in a trial of vesatolimod and broadly neutralizing antibodies in early-treated South African women with clade C HIV-1. Presented at the 13th International AIDS Society (IAS) Conference on HIV Science; July 13-17, 2025; Kigali, Rwanda. Poster WEPEB018.
  • Ahmed A, Hill M, Dong KL, Ngcobo MW, Zulu A, Langa N, Maphalala L, Pillay V, Mthembu M, Tran W, Lau R, Stockman JK, Ndung'u T, Dube K. Stress and Coping During an HIV Cure-Related Trial with an Analytical Treatment Interruption: A Qualitative Assessment of the Experiences of Young Women in Durban, South Africa. J Int Assoc Provid AIDS Care. 2026 Jan-Dec;25:23259582261423985. doi: 10.1177/23259582261423985. Epub 2026 Feb 13. PubMed 41685863 ↗
  • Ahmed A, Dong KL, Hussain M, Ngcobo MW, Langa N, Zulu A, Maphalala L, Pillay V, Mthembu M, Wan F, Tran W, Lau R, Stockman JK, Ndung'u T, Dube K. Psychological Impact of Analytical Treatment Interruption on Young Women Enrolled in an HIV Cure-Related Clinical Trial in Durban, South Africa. AIDS Res Hum Retroviruses. 2026 Mar;42(3):109-116. doi: 10.1177/08892229251405807. Epub 2026 Jan 2. PubMed 41449969 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jan 2025, 31 months.

Results were first posted in Jan 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 16, 2022
StartActual
Jun 9, 2022
Primary completionActual
Jan 16, 2025
CompletionActual
Jan 16, 2025
Results first posted
Jan 16, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05281510
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Jun 9, 2022
Primary completion
Jan 16, 2025
Completion
Jan 16, 2025
Results posted
Jan 16, 2026
Last update
Jan 16, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VRC07-523LS

Start the discussion